Professor Leslie Burnett

Clinical Professor
Genetic Medicine, Northern Clinical School

Telephone +61 2 9926 4145

Website Related website

Map

Biographical details

Dr Leslie Burnett is a Consultant Clinical Pathologist, specialising in Chemical Pathology, Genetic Pathology and Bioinformatics.

Professor Burnett has specialist qualifications in Medicine, Science, Management and Information Technology. He is Clinical Professor in Pathology and Genetic Medicine in the Northern Clinical School of the Faculty of Medicine, University of Sydney, and an Honorary Associate of the School of Information Technologies at the University of Sydney. He has authored more than 100 publications.

His achievements span an extraordinary breadth of endeavour. He has served in distinguished senior National and International professional roles in pathology, and is a current Member of the Human Genetics Advisory Committee (HGAC) of the National Health and Medical Research Council (NHMRC) of Australia (by Ministerial appointment). Previous roles have included serving as Chairman of the National Pathology Accreditation Advisory Council (NPAAC) of Australia (by Ministerial appointment), Associate Member, Medical Devices Evaluation Committee (MDEC), Commonwealth of Australia Therapeutic Goods Administration (TGA) (by Ministerial appointment), President of the Australasian Association of Clinical Biochemists (AACB), President of the National Coalition of Public Pathology (NCOPP), Chairman of the Quality Assurance, Scientific and Education Committee of the Royal College of Pathologists of Australasia (RCPA), Councillor of the Royal College of Pathologists of Australasia (RCPA), Chairman of the Benchmarking in Pathology Program, RCPA Quality Assurance Programs (RCPA QAP), Chairman of the Key Incident Monitoring and Management System Program of the RCPA QAP and Chairman of the Ethics Taskforce of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).

Dr Burnett’s past organisational roles include being founding Director and Chief Executive of the Pathology North Cluster of the NSW Health Pathology Service, Director of Pacific Laboratory Medicine Services (PaLMS) and Assistant Director of the Institute of Clinical Pathology and Medical Research (ICPMR).

Dr Burnett pioneered the development and introduction of a number of pathology, genetics and management initiatives, including Community Genetics screening in Australia, Cost Benchmarking in Pathology, Process Capability in Quality Control, pre-analytical Quality Assurance and Incident Monitoring in Pathology. Today, all these initiatives are mainstream pathology and healthcare programs. The American Association of Clinical Chemistry (AACC) has awarded him its Management Sciences Award in recognition of “achievements of an individual who has made outstanding contributions in management sciences to the clinical laboratory and healthcare industry”.

Research interests

Genetic Pathology, Bioinformatics, Quality Assurance, Accreditation

Current projects

Community genetics, Genetic screening;

Bioinformatics

Associations

Honorary Associate; School of Information Technologies

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Field, M., Burnett, L., Sullivan, D., Stewart, P. (2006). Clinical biochemistry and metabolism. In NA Boon, NR Colledge, BR Walker, JAA Hunter (Eds.), Davidson's Principles & Practice of Medicine, (pp. 419-454). Edinburgh: Churchill Livingstone.
  • Field, M., Burnett, L., Sullivan, D., Stewart, P. (2005). Biochemical Disorders. In N Boon, N Colledge, B Walker, J Hunter (Eds.), Davidson's Principles and Practice of Medicine (20 Ed.), (pp. 1-2). United Kingdom: Elsevier.
  • Field, M., Burnett, L., Sullivan, D., Stewart, P. (2005). Clinical biochemistry and metabolism. In Nicholas A. Boon, Nicki R. Colledge, Brian R. Walker and John Hunter (Eds.), Davidson's Principles and Practice of Medicine, (pp. 419-454). Churchill Livingstone.
  • Burnett, L. (2002). Pathology Indicators. In Aust Council on Healthcare Standards (Eds.), The Australian Council on Healthcare Standards: Clinical Indicator User's Manual, (pp. 231-234). Australia: Australian Council on Healthcare Standards.

Journals

  • Campbell, B., Burnett, L. (2014). Diagnosis of diabetes in anaemias and haemoglobinopathies: salutary lessons for improved reporting and patient empowerment. Pathology, 46(4), 371-372. [More Information]
  • Neil, A., Pfeffer, S., Burnett, L. (2013). Benchmarking in pathology: development of a benchmarking complexity unit and associated key performance indicators. Pathology, 45(1), 66-70. [More Information]
  • Burnett, L., Wilson, R., Pfeffer, S., Lowry, J. (2012). Benchmarking in pathology: development of an activity-based costing model. Pathology, 44(7), 644-653. [More Information]
  • Lew, R., Proos, A., Burnett, L., Delatycki, M., Bankier, A., Fietz, M. (2012). Tay Sachs disease in Australia: reduced disease incidence despite stable carrier frequency in Australian Jews. Medical Journal of Australia, 197(11/12), 652-654. [More Information]
  • Lew, R., Burnett, L., Proos, A. (2011). Tay-Sachs disease preconception screening in Australia: self-knowledge of being an Ashkenazi Jew predicts carrier state better than does ancestral origin, although there is an increased risk for c.1421 + 1G > C mutation in individuals with South African heritage. Journal of Community Genetics, 2(4), 201-209. [More Information]
  • Burnett, D., Burnett, L. (2010). A rare granulomatous reaction to Q fever vaccination following influenza vaccination. Medical Journal of Australia, 193(1), 60. [More Information]
  • Burnett, L., McQueen, M., Jonsson, J., Torricelli, F. (2007). IFCC Position Paper: Report of the IFCC Taskforce on Ethics: Introduction and framework. Clinical Chemistry and Laboratory Medicine, 45(8), 1098-1104. [More Information]
  • Barlow-Stewart, K., Burnett, L. (2006). Ethical considerations in the use of DNA for the diagnosis of diseases. Clinical Biochemist Reviews, 27(1), 53-61. [More Information]
  • Warren, E., Anderson, R., Proos, A., Burnett, L., Barlow-Stewart, K., Hall, J. (2005). Cost-effectiveness of a school-based Tay-Sachs and cystic fibrosis genetic carrier screening program. Genetics in Medicine, 7(7), 484-494. [More Information]
  • McKenzie, S., Deane, E., Burnett, L. (2004). Are Serum Cortisol Levels A Reliable Indicator Of Wellbeing In The Tammar Wallaby, Macropus Eugenii? Comparative Biochemistry and Physiology. Part A: Molecular and Integrative Physiology, 138(3), 341-348.
  • Howell, V., Proos, A., La Rue, D., Jensen, C., Beach, F., Burnett, L. (2004). Carrier Screening For Canavan Disease In Australia. Journal of Inherited Metabolic Disease (JIMD), 27(2), 289-290.
  • Burnett, L., Chesher, D., Mudaliar, Y. (2004). Improving The Quality Of Information On Pathology Request Forms. Annals of Clinical Biochemistry: an international journal of biochemistry in medicine, 41(1), 53-56.
  • Barlow-Stewart, K., Burnett, L., Proos, A., Howell, V., Huq, F., Lazarus, R., Aizenberg, H. (2003). A genetic screening programme for Tay-Sachs disease and cystic fibrosis for Australian Jewish high School students. Journal of Medical Genetics, 40(e45), 1-8.
  • Burnett, L. (2003). Making national DNA databases safer. The Lancet, 362(9397), 1761-1762.
  • Burnett, L., Barlow-Stewart, K., Proos, A., Aizenberg, H. (2003). The "GeneTrustee": a universal identificaiton system that ensures privacy and confidentiality for human genetic databases. Journal of Law and Medicine, 10(4), 506-513.
  • Burnett, L., Chesher, D., Groot-Obbink, D., Hegedus, G., Mackay, M., Proos, A., Rochester, C., Shaw, W., Webber, A. (2002). ISO compliant laboratory quality systems and incident monitoring improve the implementation of laboratory information systems. Accreditation And Quality Assurance, 7(6), 237-241.
  • Burnett, L., Chesher, D., Burnett, J. (2002). Optimizing the availability of 'stat' laboratory tests using Shewhart 'c' control charts. Annals of Clinical Biochemistry: an international journal of biochemistry in medicine, 39(2), 140-144.

Conferences

  • Burnett, L., McQueen, M., Jonsson, J., Torricelli, F. (2004). The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Ethics Committee: Proposed policy and draft ethics framework. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).

2014

  • Campbell, B., Burnett, L. (2014). Diagnosis of diabetes in anaemias and haemoglobinopathies: salutary lessons for improved reporting and patient empowerment. Pathology, 46(4), 371-372. [More Information]

2013

  • Neil, A., Pfeffer, S., Burnett, L. (2013). Benchmarking in pathology: development of a benchmarking complexity unit and associated key performance indicators. Pathology, 45(1), 66-70. [More Information]

2012

  • Burnett, L., Wilson, R., Pfeffer, S., Lowry, J. (2012). Benchmarking in pathology: development of an activity-based costing model. Pathology, 44(7), 644-653. [More Information]
  • Lew, R., Proos, A., Burnett, L., Delatycki, M., Bankier, A., Fietz, M. (2012). Tay Sachs disease in Australia: reduced disease incidence despite stable carrier frequency in Australian Jews. Medical Journal of Australia, 197(11/12), 652-654. [More Information]

2011

  • Lew, R., Burnett, L., Proos, A. (2011). Tay-Sachs disease preconception screening in Australia: self-knowledge of being an Ashkenazi Jew predicts carrier state better than does ancestral origin, although there is an increased risk for c.1421 + 1G > C mutation in individuals with South African heritage. Journal of Community Genetics, 2(4), 201-209. [More Information]

2010

  • Burnett, D., Burnett, L. (2010). A rare granulomatous reaction to Q fever vaccination following influenza vaccination. Medical Journal of Australia, 193(1), 60. [More Information]

2007

  • Burnett, L., McQueen, M., Jonsson, J., Torricelli, F. (2007). IFCC Position Paper: Report of the IFCC Taskforce on Ethics: Introduction and framework. Clinical Chemistry and Laboratory Medicine, 45(8), 1098-1104. [More Information]

2006

  • Field, M., Burnett, L., Sullivan, D., Stewart, P. (2006). Clinical biochemistry and metabolism. In NA Boon, NR Colledge, BR Walker, JAA Hunter (Eds.), Davidson's Principles & Practice of Medicine, (pp. 419-454). Edinburgh: Churchill Livingstone.
  • Barlow-Stewart, K., Burnett, L. (2006). Ethical considerations in the use of DNA for the diagnosis of diseases. Clinical Biochemist Reviews, 27(1), 53-61. [More Information]

2005

  • Field, M., Burnett, L., Sullivan, D., Stewart, P. (2005). Biochemical Disorders. In N Boon, N Colledge, B Walker, J Hunter (Eds.), Davidson's Principles and Practice of Medicine (20 Ed.), (pp. 1-2). United Kingdom: Elsevier.
  • Field, M., Burnett, L., Sullivan, D., Stewart, P. (2005). Clinical biochemistry and metabolism. In Nicholas A. Boon, Nicki R. Colledge, Brian R. Walker and John Hunter (Eds.), Davidson's Principles and Practice of Medicine, (pp. 419-454). Churchill Livingstone.
  • Warren, E., Anderson, R., Proos, A., Burnett, L., Barlow-Stewart, K., Hall, J. (2005). Cost-effectiveness of a school-based Tay-Sachs and cystic fibrosis genetic carrier screening program. Genetics in Medicine, 7(7), 484-494. [More Information]

2004

  • McKenzie, S., Deane, E., Burnett, L. (2004). Are Serum Cortisol Levels A Reliable Indicator Of Wellbeing In The Tammar Wallaby, Macropus Eugenii? Comparative Biochemistry and Physiology. Part A: Molecular and Integrative Physiology, 138(3), 341-348.
  • Howell, V., Proos, A., La Rue, D., Jensen, C., Beach, F., Burnett, L. (2004). Carrier Screening For Canavan Disease In Australia. Journal of Inherited Metabolic Disease (JIMD), 27(2), 289-290.
  • Burnett, L., Chesher, D., Mudaliar, Y. (2004). Improving The Quality Of Information On Pathology Request Forms. Annals of Clinical Biochemistry: an international journal of biochemistry in medicine, 41(1), 53-56.
  • Burnett, L., McQueen, M., Jonsson, J., Torricelli, F. (2004). The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Ethics Committee: Proposed policy and draft ethics framework. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).

2003

  • Barlow-Stewart, K., Burnett, L., Proos, A., Howell, V., Huq, F., Lazarus, R., Aizenberg, H. (2003). A genetic screening programme for Tay-Sachs disease and cystic fibrosis for Australian Jewish high School students. Journal of Medical Genetics, 40(e45), 1-8.
  • Burnett, L. (2003). Making national DNA databases safer. The Lancet, 362(9397), 1761-1762.
  • Burnett, L., Barlow-Stewart, K., Proos, A., Aizenberg, H. (2003). The "GeneTrustee": a universal identificaiton system that ensures privacy and confidentiality for human genetic databases. Journal of Law and Medicine, 10(4), 506-513.

2002

  • Burnett, L., Chesher, D., Groot-Obbink, D., Hegedus, G., Mackay, M., Proos, A., Rochester, C., Shaw, W., Webber, A. (2002). ISO compliant laboratory quality systems and incident monitoring improve the implementation of laboratory information systems. Accreditation And Quality Assurance, 7(6), 237-241.
  • Burnett, L., Chesher, D., Burnett, J. (2002). Optimizing the availability of 'stat' laboratory tests using Shewhart 'c' control charts. Annals of Clinical Biochemistry: an international journal of biochemistry in medicine, 39(2), 140-144.
  • Burnett, L. (2002). Pathology Indicators. In Aust Council on Healthcare Standards (Eds.), The Australian Council on Healthcare Standards: Clinical Indicator User's Manual, (pp. 231-234). Australia: Australian Council on Healthcare Standards.

To update your profile click here. For support on your academic profile contact .